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bjectives This study evaluated the antiplatelet effect of a higher loading and maintenance dose
egimen of clopidogrel and a possible drug interaction with verapamil.
ackground Clopidogrel loading doses above 600 mg have not resulted in more rapid or complete
latelet inhibition. Higher maintenance dosages may be more effective than 75 mg/day.
ethods A double-blind, randomized, placebo-controlled trial was undertaken in 60 patients under-
oing percutaneous coronary intervention. All patients received clopidogrel 600 mg at the start of
he procedure. Using a 2  2 design, patients were allocated to clopidogrel 600 mg given 2 h later
r matching placebo, and to verapamil 5 mg intra-arterial or placebo. Platelet function was mea-
ured using the VerifyNow P2Y12 analyzer (Accumetrics Ltd., San Diego, California) at 2, 4, and 7 h.
atients were further randomized to receive a clopidogrel 75 or 150 mg once daily, with platelet
unction assessed after 1 week.
esults Two hours after the second dose of clopidogrel or placebo, platelet inhibition was 42  27%
ith clopidogrel, compared with 24  22% with placebo (p  0.0006). By 5 h after the second dose,
latelet inhibition was 49  30% with clopidogrel, compared with 29  22% with placebo (p  0.01).
o drug interaction was seen with verapamil. A clopidogrel maintenance dosage of 150 mg daily for 1
eek resulted in greater platelet inhibition than 75 mg daily (50  28% vs. 29  19%, p  0.01).
onclusions In an unselected population undergoing percutaneous coronary intervention a clopi-
ogrel 1,200-mg loading dose, given as two 600-mg doses 2 h apart, results in more rapid and com-
lete platelet inhibition than a single 600-mg dose. A maintenance dosage of 150 mg daily pro-
uces greater platelet inhibition than 75 mg daily. (The PRINC trial; ACTRN12606000129583) (J Am
oll Cardiol Intv 2008;1:612–9) © 2008 by the American College of Cardiology Foundation
rom *Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand; and the †Department of Medical
ciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden. This study was funded in part by the Green Lane Research
nd Educational Fund and National Heart Foundation of New Zealand. The VerifyNow Platelet function analyzer was provided
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613loading dose of 600-mg clopidogrel given immediately
efore percutaneous coronary intervention (PCI) achieves
reater platelet inhibition and reduces periprocedural myo-
ecrosis, compared with lower dosages (1,2). Three studies
ave examined whether a 900-mg loading dose might be
ven more effective. Two showed no further platelet inhi-
ition with 900 mg compared with 600 mg (3,4), but in the
hird, there was a nonsignificant trend to greater platelet
nhibition that was only evident 6 h after dosing (5).
lopidogrel drug levels measured in the ISAR-CHOICE
Intracoronary Stenting and Antithrombotic Regimen:
hoose Between 3 High Oral Doses for Immediate Clopi-
ogrel Effect) study suggested that the ceiling effect with
lopidogrel 600 mg might be due to saturable intestinal
bsorption of the drug (3). Split-dose loading with clopi-
ogrel may overcome this limitation and achieve greater
latelet inhibition (3,4).
See page 628
P-glycoprotein is a drug efflux pump mechanism in the
ut that may reduce the intestinal absorption of clopidogrel
6). Verapamil, a vasodilator drug frequently used in the
ardiac catheterization laboratory, inhibits p-glycoprotein in
he short term but up-regulates it in the long term.
erapamil also inhibits CYP3A4, thereby potentially inter-
ering with clopidogrel pharmacokinetics (7).
We undertook a randomized, placebo-controlled trial to
ompare the effect of a clopidogrel 1,200-mg split-loading
ose with a standard 600-mg loading dose and to assess
possible interaction between verapamil and clopidogrel.
higher maintenance dosage regimen of clopidogrel was
lso evaluated.
ethods
tudy population. The study protocol was approved by the
orthern Regional Ethics Committee of New Zealand and
egistered with the Australian New Zealand Clinical Trials
egistry (ACTRN12606000129583). Consecutive patients
ndergoing elective PCI, who were taking aspirin but not
lopidogrel, were enrolled in the study. Exclusion criteria
ere a bleeding or inherited platelet disorder; gastrointes-
inal bleeding or gastric ulcer, duodenal ulcer, or gastritis
ithin the last 6 months; sensitivity and/or allergy to
spirin, clopidogrel, or verapamil; renal failure (creatinine
learance estimated glomerular filtration rate: 30 ml/s/
2); anemia (hemoglobin 11.5 g/dl); thrombocytopenia
platelet count150 109/l); use of a glycoprotein IIb/IIIa
nhibitor and medications inhibiting CYP3A4. Patients on
arfarin were eligible if the international normalized ratio
as 1.5 at study entry and warfarin could be withheld forhe 7-day study duration. vtudy design. The study design had 2 phases: a 2  2
actorial, randomized, placebo-controlled, double-blind
tudy over the first 24 h, followed by a 1-week randomized,
lacebo-controlled, double-blind study. Randomization was
one by computerized pseudorandom number. Clopidogrel
as repackaged into gelatin capsules packed with lactose
owder to match the appearance of the placebo capsules.
Patients were first randomized in a 2  2 manner to
eceive either 5-mg intra-arterial verapamil or placebo at
aseline and either placebo or 600-mg clopidogrel, 2 h from
aseline (Fig. 1). Verapamil 5 mg approximates the dose
sed in clinical practice. All patients received 600-mg
lopidogrel at the start of the PCI procedure, 10 min after
dministration of verapamil or placebo. Starting the next
ay, all patients were separately randomized to receive
lopidogrel 75 or 150 mg once daily for 1 week, followed by
5 mg once daily thereafter. Adherence to the treatment
egimen was assessed by phone interview and pill count.
lood sampling. Arterial blood was sampled through a 6-F
emoral sheath and transferred immediately to 3.2% citrate
-ml vacutainer tubes (Greiner Vacuette, Greiner, Krems-
uenster, Austria), using a 20-G needle and syringe. After
heath removal, blood was
rawn by venipuncture directly
nto vacutainer tubes. The col-
ection tubes were inverted 4
imes to mix the anticoagulant
nd left for 10 min at ambient
emperature (24°C) before test-
ng. Platelet function was tested
t baseline, 2, 4, and 7 h from
he first clopidogrel loading
ose; and at 7 days.
latelet function analysis. Platelet function was measured
sing the VerifyNow point-of-care rapid platelet function
nalyzer (RPFA) and its P2Y12 cartridge (Accumetrics
td., San Diego, California). This device uses fibrinogen-
oated microbeads, an agonist of adenosine diphosphate (20
mol/l), and light transmittance through whole blood to
easure platelet agglutination. The P2Y12 cartridge result
orrelates favorably with light transmittance aggregometry
8), with a reported increased sensitivity to the P2Y12
eceptor due to the addition of prostaglandin E2 (22 nmol/l)
o the reaction chamber (9). Platelet inhibition is reported as
he percentage change in the platelet response unit (PRU)
rom a baseline unit, derived from a second channel run in
arallel with the adenosine diphosphate channel using the
gonist isothrombin receptor activating peptide.
Antiplatelet drug “resistance” may be assessed as residual
ost-treatment activity in the target pathway of an anti-
latelet agent (10). Nonresponsiveness to clopidogrel was
efined as 10% maximal inhibition at 7 h (11,12).
nd points. The study primary end points were RPFA
Abbreviations
and Acronyms
PCI  percutaneous
coronary intervention
PRU  platelet response
unit
RPFA  rapid platelet
function analyzeralues at 2, 4, and 7 h for verapamil; 4 and 7 h for
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614lopidogrel loading; and 7 days for the clopidogrel mainte-
ance dose. The 7-h value was considered the peak loading
ose effect.
Secondary end points were plasma troponin and creatine
inase at 7 h and safety outcomes including death, myocar-
ial infarction, bleeding events, and adverse drug reactions.
ignificant bleeding was defined as any intracranial bleed-
ng, hemoglobin decrease of 5 g/dl, bleeding requiring
ransfusion, femoral hematoma 10-cm diameter, or fem-
ral pseudoaneurysm.
tatistical analysis. With the 2  2 design, it was estimated
hat 120 patients (30 in each group) would provide 80%
ower to detect 1 standardized difference between groups in
he percentage platelet inhibition, at a significance level of
.05. An interim analysis was prespecified once 60 patients
ere enrolled. As verapamil had no effect, the verapamil and
lacebo results were combined, giving 60 subjects in which
o compare the 600-mg and 1,200-mg doses over the first
4 h, and the 75-mg and 150-mg dosages at 1 week.
Chi-square likelihood ratio tests were used to compare
ategorical outcomes between the different intervention
roups; Fisher exact tests were used where more than 25%
f the expected counts in a table were less than 5. The
ann-Whitney U test was applied to compare continuous
easures between groups. Analysis of covariance was used
o adjust for baseline PRU and age when comparing
ercentage platelet inhibition in the 600-mg and 1,200-mg
lopidogrel groups and to adjust for baseline PRU, age, and
iabetes in the 75-mg and 150-mg clopidogrel groups.
qual variances tests were applied. The effect of the loading
ose on platelet inhibition at 1 week was nonsignificant and
he results at 1 week, across loading doses, were pooled into
Figure 1. Study Protocol TimelineThe ﬁgure shows the PRINC trial protocol.ust 75-mg and 150-mg groups. A kinetic model on
ogarithmic scale of hours was used to describe the growth
ate of percentage platelet inhibition over time. The model
as validated by undertaking linear regression on each
atient’s percentage platelet inhibition versus the natural
ogarithm of hours after medication. Coefficient of deter-
inants R2 were summarized and compared across 2 other
inetic models (Ln[%inhibition]  Ln[hours] and %inhi-
ition  exp[hours]). Two-sided tests were used in all
nalyses and a p value 0.05 was considered statistically
ignificant. The software used for the analysis was Statistics
nalysis System (version 9.1) and R (version 2.1.1) (SAS
nstitute, Cary, North Carolina).
esults
atient characteristics. Patients were well matched between
reatment groups with similar baseline demographics, pre-
xisting illnesses, smoking rates, and current medications
Table 1). The average age was greater in the verapamil
roup, and there were more patients with diabetes in the
lopidogrel 150-mg group. Baseline PRU and percentage
latelet inhibition did not differ significantly at baseline or
h after all patients received the first clopidogrel 600-mg
ose. The treatment group numbers differed, as a block
andomization schedule was not used, and enrollment was
topped at 60 participants.
All participants completed the treatment allocated in the
rst stage of the protocol. Three outlier RPFA values were
bserved at baseline, but were included in the analysis,
ossibly indicating either sampling error or inadvertent
dministration of clopidogrel prior to PCI. Three outlier
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615alues in the post-loading phase, thought to be related to
verfilled citrate tubes, were also included. A total of 15
ubjects (12 in the 150-mg group and 3 in the 75-mg group)
id not have the 1-week follow-up RPFA because they lived
ore than 2 h from the tertiary PCI center.
rimary outcomes. Platelet inhibition at 2 h did not differ in
he group receiving verapamil compared with placebo group
20.9  23.1% vs. 17.0  17.5%, p  0.4). There was also
o difference seen at 4 or 7 h (Table 2).
Platelet inhibition at 4 h differed significantly between
he 600-mg loading dose and the 1,200-mg split loading
Table 1. Patient Characteristics
N  60
60
Demographics
Age, yrs, mean (SD) 68 (10)
Male 50 (83%)
Caucasian 57 (95%)
BMI, kg/m2, mean (SD) 29 (4)
Current smoker 6 (10%)
Baseline PRU 346.2 (58)
Clinical characteristics
ASA 59 (98%)
Statin 56 (95%)
Beta-blocker 47 (80%)
ACE 33 (56%)
DM 11 (18%)
HTN 34 (57%)
CHF 2 (3%)
Prior CABG 6 (10%)
Recent NSTEMI 4 (7%)
Recent STEMI 3 (5%)
Prior PCI 12 (20%)
PVD 13 (22%)
Family history of CAD 24 (40%)
Ejection fraction, mean (SD) 68 (16)
Multiple stents 9 (15%)
DES 21 (35%)
ACE  angiotensin-converting enzyme; ASA acetylsalicylic acid; BMI  body mass index; CABG
drug-eluting stent; DM  diabetes mellitus; HTN  hypertension; NSTEMI  non–ST-segment ele
PVD pulmonary vascular disease; STEMI ST-segment elevation myocardial infarction.
Table 2. Percentage Platelet Inhibition (Mean [SD]) in Patients Receiving
Clopidogrel and Verapamil
Placebo Verapamil
Baseline 7.4 (15.0) 2.2 (3.9)
2 h 17.0 (17.5) 20.9 (23.1)
4 h 32.9 (27.1) 37.6 (25.5)
7 h 40.4 (30.5) 42.1 (27.8)
7 days 40.8 (23.7) 41.1 (28.6)*Mann-Whitney U test. †Analysis of covariance, adjusted by baseline platelet response unit and age.ose (23.7  21.6% vs. 42  26.6%, p  0.03). This
ifference was sustained at 7 h (28.7  21.9% vs. 48.9 
0.3%, p  0.03) (Fig. 2) but not at 7 days (35.7  27.3%
s. 44.5  25.8%, p  0.3). Analysis of the 4- and 7-h
esults using analysis of covariance to adjust for baseline
ifferences in age, baseline PRU, and any interaction be-
ween drugs and dose showed that the treatment group
ifferences remained significantly different (p  0.01).
The rate of change over time in platelet inhibition in the
,200-mg split dose group was significantly greater than in
he 600-mg group. Linear percentage inhibition change by
idogrel
 Placebo
23)
Clopidogrel
600 mg  600 mg
(n  37) p Value
(10) 70 (10) 0.06
(83%) 31 (84%) 0.9
(96%) 35 (95%) 0.3
(4) 29 (5) 0.4
(13%) 3 (8%) 0.7
(45) 353 (64) 0.1
(100%) 36 (97%) 0.9
(95%) 35 (95%) 0.9
(73%) 31 (84%) 0.3
(59%) 20 (54%) 0.7
(17%) 7 (19%) 0.9
(65%) 19 (51%) 0.3
(4%) 1 (3%) 0.9
(4%) 5 (14%) 0.4
(9%) 2 (5%) 0.6
(9%) 1 (3%) 0.6
(22%) 7 (19%) 0.9
(22%) 8 (22%) 0.9
(52%) 12 (32%) 0.1
(24) 71 (11) 0.3
(9%) 7 (19%) 0.5
(30%) 14 (38%) 0.6
nary artery bypass graft; CAD  coronary artery disease; CHF  congestive heart failure; DES 
myocardial infarction; PCI  percutaneous coronary intervention; PRU  platelet response unit;
ogrel and Placebo Compared With Those Receiving
Unadjusted p Value* Adjusted p Value†
0.3
0.6 0.2
0.4 0.5
0.7 0.3
0.9 0.6Clop
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616og (hours) was 43% versus 14%, respectively, at 4 h (p 
.0001) (Table 3).
At 1 week, a significant difference in platelet inhibition
as seen between the group receiving 75 mg of clopidogrel
ompared with the group receiving 150-mg once daily (28.8
19.4% vs. 49.8  27.7%, p  0.01) (Figs. 3 and 4). The
egree of platelet inhibition 7 h after the 1,200-mg loading
ose was similar to that achieved after a maintenance dose
f 150 mg/day for 7 days.
econdary outcomes. Troponin levels at 7 h were signifi-
antly higher in patients considered nonresponsive to clo-
idogrel compared with those who were responsive (me-
ian: 0.05 [0.01, 0.29] vs. 0.01 [0.01, 0.03], p  0.05).
owever, there was no significant difference in 7-h troponin
evels between the 1,200-mg and 600-mg loading dose
roups (median: 0.04 [0.01, 0.23] vs. 0.01 [0.01, 0.03], p 
.5).
Figure 2. Temporal Dose Response Showing Platelet Inhibition in
Patients Receiving 600-mg and 1,200-mg Clopidogrel Loading Doses
The points represent the mean platelet inhibition and the bars represent
the 95% conﬁdence intervals. The unadjusted p value is from Mann-
Whitney U test. This result was adjusted by baseline platelet response unit
and age level using analysis of covariance.
Table 3. Percentage Platelet Inhibition Growth Rate (Median [IQR]) in
Patients Receiving Clopidogrel 600 mg at Baseline Compared With Clopidogrel
600 mg at Baseline and a Second Dose of Clopidogrel 600 mg at 2 h
Clopidogrel 600 mg
 Placebo
Clopidogrel 600 mg
 600 mg p Value*
2 h 16 (0, 30) 13 (3, 39) 0.9
4 h 14 (2, 24) 43 (29, 62) 0.0001
7 h 15 (3, 20) 24 (12, 37) 0.009
The data presented are median (IQR). The unit is %change/Ln (hour). *Mann-Whitney U test.CI confidence interval; IQR interquartile range.In the 1,200-mg group, there were 3 gastrointestinal
dverse reactions: 1 patient vomited, 1 experienced indiges-
ion, and another developed diarrhea the next day, which
as thought to be due to the lactose vehicle in the gelatin
apsules.
Figure 3. Platelet Inhibition in Patients Receiving 75-mg and 150-mg
Once Daily Clopidogrel After 1 Week
Unadjusted p value is from Mann-Whitney U test. This result was adjusted
by baseline platelet function analyzer level, age, and diabetes using analy-
sis of covariance.
Figure 4. Platelet Inhibition at 7 h and Effect of the Loading Dose on
Inhibition at 1 Week
Numbers in each group: 600 mg  75 mg, n  10; 1,200 mg  75 mg,
n  12; 600 mg  150 mg, n  13; 1,200 mg  150 mg, n  25.
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617There were 2 significant bleeding events, both femoral
ematomas at the groin puncture site and both in study
ubjects in their 80s. Neither required blood transfusion.
ne subject was in the 1,200-mg dose and the other in the
00-mg dose group; P2Y12 platelet inhibition at the time of
leeding was 28% and 25%, respectively. There were no
pontaneous bleeding episodes. Adherence to treatment at 1
eek was 89%.
iscussion
clopidogrel 1,200-mg loading dose achieves more rapid
nd complete platelet inhibition than a 600-mg loading
ose does, if administered as two 600-mg doses given 2 h
part. Greater platelet inhibition was evident within 2 h of
he second 600-mg dose. Until now, the ceiling loading
ose of clopidogrel appeared to be 600 mg. Staggered
osing may be more effective by overcoming the saturable
ature of intestinal absorption of the parent drug (3).
nother possible explanation is that circulating platelets
ave longer exposure to the primary metabolite of clopi-
ogrel. This primary metabolite has a short half-life and is
reated by the hepatic biotransformation of the parent drug
y cytochrome P450 3A4, 1A2, 2B6, 2C19, and 2C9
13–15).
Consistent findings were recently reported in the PRE-
AIR (Clopidogrel 600-mg Double Loading Dose
chieves Stronger Platelet Inhibition than Conventional
egimens) study, which demonstrated that platelet inhibi-
ion was increased after a second 600-mg dose of clopi-
ogrel given 18 to 24 h after an initial 600-mg loading dose
16). In another study of patients undergoing stent deploy-
ent, a standard clopidogrel 600-mg loading dose was
ompared with vasodilator-stimulated phosphoprotein–
uided clopidogrel reloading, with up to 3 additional daily
00-mg doses (17). The vasodilator-stimulated phospho-
rotein–guided treatment group had significantly fewer
0-day adverse cardiac events, with no increased bleeding.
Although a larger trial is needed to confirm the clinical
fficacy and safety of this regimen, other studies have related
he degree of platelet inhibition to periprocedural myone-
rosis (2). In the CREDO (Clopidogrel for Reduction of
vents During Observation) study, an early and sustained
ntiplatelet effect, achieved by dosing more than 6 h before
CI, was necessary to reduce the combined risk of death,
yocardial infarction, or urgent target vessel revasculariza-
ion (18). The ISAR-REACT 2 (Intracoronary Stenting
nd Antithrombotic REgimen: Rapid Early Action for
oronary Treatment) study demonstrated that clopidogrel
00 mg given 2 h or more before intervention was insuffi-
ient to achieve optimal platelet inhibition in high-risk
roponin-positive acute coronary syndrome patients. In that
tudy, adding abciximab reduced adverse events (19). It is
ossible that a clopidogrel regimen with a higher loading 1nd maintenance dosage might have achieved a similar
utcome.
Optimal loading dosage regimens of clopidogrel are
mportant because pre-treatment is not always logistically
ossible or clinically desirable. Clopidogrel loading before
ngiography in patients who subsequently need early coro-
ary bypass graft surgery is a problem, as it is associated with
50% increase in major perioperative bleeding (20).
Another major finding is that, in an unselected popula-
ion, a maintenance clopidogrel dosage of 150 mg daily
chieves greater chronic platelet inhibition than the stan-
ard regimen of 75 mg daily. This is consistent with a study
y Kastrati et al. (21) showing that in patients on chronic
lopidogrel 75 mg daily, reloading with 600-mg clopidogrel
t the time of coronary intervention achieves greater platelet
nhibition. The OPTIMUS (Optimizing Antiplatelet
herapy in Diabetes Mellitus) study also showed greater
latelet inhibition with 150-mg than 75-mg clopidogrel
aily. That study selectively enrolled patients with diabetes
ho had demonstrated a suboptimal response to clopidogrel
5 mg daily, as assessed by light transmittance aggregometry
22). It is at present unclear whether this increased anti-
latelet effect will translate into a reduction in adverse
linical events without an undue increase in bleeding. The
ngoing CURRENT/OASIS-7 (Clopidogrel Optimal
oading Dose Usage to Reduce Recurrent Events/Optimal
ntiplatelet Strategy for Interventions) study will answer
ome of these questions; approximately 14,000 non–
T-segment elevation myocardial infarction patients are
eing randomly allocated to clopidogrel treatment with
ither a 600-mg loading dose, followed by 150 mg once
aily for the first week of therapy or to a 300-mg loading
ose, followed by 75 mg daily (23).
Drug–drug interactions are a common cause of hospital
orbidity. Atorvastatin and erythromycin interact with
lopidogrel by affecting hepatic biotransformation. Al-
hough the ex vivo antiplatelet effect of clopidogrel is
educed, nonrandomized clinical studies to date have not
emonstrated worse clinical outcomes (24). Verapamil has
ixed and unexpected effects on the intestinal p-glycopro-
ein efflux pump. Short-term dosing inhibits p-glycoprotein
ctivity, potentially enhancing clopidogrel absorption,
hereas longer term dosing up-regulates p-glycoprotein and
ay have the opposite effect. Verapamil also has an inhib-
tory effect on cytochrome P450 3A4 metabolism, which
ould reduce the biotransformation of clopidogrel. We
ound that a single dose of verapamil did not impair the
ntiplatelet effect of clopidogrel.
The extent of platelet inhibition at 7 h with the split
,200-mg loading dose was similar to that achieved with
50-mg clopidogrel daily for 1 week, supporting the idea to
se such a regimen in future clinical trials. Although our
tudy lacked sufficient power to determine whether the
,200-mg loading dose reduced post-PCI troponin eleva-
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618ion, we did confirm previous reports that those who were
nresponsive to clopidogrel were significantly more likely to
ave periprocedural myonecrosis.
The TRITON–TIMI-38 (Trial to Assess Improvement
n Therapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction-38)
tudy reported that prasugrel given as a 60-mg loading dose
ollowed by 10-mg/day reduced post-PCI ischemic events
ompared with clopidogrel 300-mg loading dose and 75
g/day, although bleeding was increased with prasugrel
25). More recently PRINCIPLE–TIMI-44 (The Prasugrel
n Comparison to Clopidogrel for Inhibition of Platelet
ctivation and Aggregation–Thrombolysis In Myocardial
nfarction-44) study found that the same prasugrel regimen
roduced greater platelet inhibition than clopidogrel
00-mg loading followed by 150 mg/day (26). How pra-
ugrel would compare with a clopidogrel 1,200-mg loading
egimen remains to be seen. Even with a 1,200-mg loading
ose, the range of platelet response appears wider with
lopidogrel than prasugrel. Thirteen percent of patients in
he present study had10% inhibition at 7 h; these patients
ay particularly benefit from prasugrel.
tudy limitations. The clopidogrel loading dose of 1,200 mg
nd maintenance dosage of 150 mg daily appeared to be safe
nd well tolerated. The small study population precludes an
ccurate safety assessment, which awaits the results of the
ASIS-7 trial. Platelet function was only assessed with the
oint-of-care platelet function analyzer. The VerifyNow
evice lacks dynamic range compared with light transmit-
ance aggregometry and loses sensitivity below inhibition
evels of 20% (27). However, results from the VerifyNow
evice correlate well with those of light transmittance
ggregometry (8,27) through most of the platelet reactivity
ange. The results also correlate well with specific markers
f P2Y12 platelet activity such as vasodilator-stimulated
hosphorylation (9). Pharmacokinetic measurements would
ave enhanced the study. However the active metabolite of
lopidogrel is difficult to measure, requiring a derivatization
gent to protect the thiol ester (28). The numbers in the
reatment groups in this study were uneven because block
andomization was not used and the study was stopped after
he planned interim analysis.
eprint requests and correspondence: Dr. Patrick Gladding,
reen Lane Cardiovascular Service, Auckland City Hospital,
rivate Bag 92 024, Auckland 1030, New Zealand. E-mail:
atrickg@adhb.govt.nz.
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